Researchers have discovered that MASLD can progress in very different ways. New studies show that dividing patients into different groups (clusters) can help to better understand the disease and provide more targeted treatment. Two groups are particularly important: one with a high risk of liver problems and one with a high risk of heart disease and diabetes.
In a News & Views article in Nature Reviews Gastroenterology & Hepatology, DZD scientist Norbert Stefan and Giovanni Targher, University of Verona, discuss these new findings on the heterogeneity of MASLD. The current research findings could advance precision medicine and lead to better therapies for MASLD.